Exogenous levodopa is not toxic to elderly subjects with non-parkinsonian movement disorders: further clinical evidence

[1]  W. Weiner,et al.  Gait abnormality in essential tremor , 2004, Movement disorders : official journal of the Movement Disorder Society.

[2]  Y. Agid,et al.  Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions , 1998, Annals of neurology.

[3]  R. Roth,et al.  Comparison of neurotoxicity following repeated administration of l-dopa, d-dopa and dopamine to embryonic mesencephalic dopamine neurons in cultures derived from Fisher 344 and Sprague-Dawley donors. , 1997, Cell transplantation.

[4]  Y. Agid,et al.  Absence of neurotoxicity of chronic L‐DOPA in 6‐hydroxydopaminelesioned rats , 1997, Neuroreport.

[5]  A. Barzilai,et al.  Levodopa induces apoptosis in cultured neuronal cells—A possible accelerator of nigrostriatal degeneration in Parkinson's disease? , 1997, Movement disorders : official journal of the Movement Disorder Society.

[6]  M. Mena,et al.  Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants , 1995, Brain Research.

[7]  P. Lai,et al.  Resting tremor only: a variant of Parkinson's disease or of essential tremor , 1995, Journal of the Neurological Sciences.

[8]  C. Waters,et al.  Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA. Implications for the treatment of Parkinson's disease. , 1995, The Journal of clinical investigation.

[9]  S. Fahn,et al.  Antiparkinsonian therapies and brain mitochondrial complex I activity , 1995, Movement disorders : official journal of the Movement Disorder Society.

[10]  J. Jankovic,et al.  Tremor and longevity in relatives of patients with Parkinson's disease, essential tremor, and control subjects , 1995, Neurology.

[11]  H. M. Geller,et al.  l‐DOPA Cytotoxicity to PC12 Cells in Culture Is via Its Autoxidation , 1995, Journal of neurochemistry.

[12]  M. Sambrook,et al.  Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism , 1993, Brain Research.

[13]  P. Thompson,et al.  Isolated tremor and disruption of the nigrostriatal dopaminergic system , 1992, Neurology.

[14]  E. Abercrombie,et al.  Neurochemical Responses to 6‐Hydroxydopamine and L‐Dopa Therapy: Implications for Parkinson's Disease a , 1992, Annals of the New York Academy of Sciences.

[15]  T. Di Paolo,et al.  Levodopa-Induced Dyskinesia: Facts and Fancy. What Does the MPTP Monkey Model Tell Us? , 1992, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[16]  M. Horstink,et al.  Is levodopa harmful? , 1991, The Lancet.

[17]  F. Mcdowell,et al.  “Early” initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease , 1991, Neurology.

[18]  S. Iversen,et al.  Nigrostriatal damage is required for induction of dyskinesias by L-DOPA in squirrel monkeys. , 1990, Clinical neuropharmacology.

[19]  J G Nutt,et al.  Levodopa‐induced dyskinesia , 1990, Neurology.

[20]  T. Chase,et al.  Pathogenesis of dyskinesias in parkinson's disease , 1989, Annals of neurology.

[21]  Y. Agid,et al.  Does levodopa aggravate Parkinson's disease? , 1988, Neurology.

[22]  J. Meerwaldt,et al.  Factors that influence the occurrence of response variations in Parkinson's disease , 1987, Annals of neurology.

[23]  W. Poewe,et al.  Low‐dose L‐dopa therapy in Parkinson's disease , 1986, Neurology.

[24]  J. Jankovic,et al.  The heterogeneity of Parkinson's disease , 1985, Neurology.

[25]  R P Lesser,et al.  Analysis of the clinical problems in parkinsonism and the complications of long‐term levodopa therapy , 1979, Neurology.

[26]  M. Yahr,et al.  Autopsy findings in parkinsonism following treatment with levodopa , 1972, Neurology.

[27]  D. Riley.  Is levodopa toxic to human substantia nigra? , 1998, Movement disorders : official journal of the Movement Disorder Society.

[28]  Y. Agid,et al.  Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. , 1997, Histology and histopathology.

[29]  P. Vieregge,et al.  EXTRAPYRAMIDAL-MOTORISCHE STORUNGEN UND DEPRESSION UNTER FLUNARIZIN-THERAPIE , 1992 .

[30]  N. Quinn,et al.  Preservation of the substanitia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four‐year period , 1986, Movement disorders : official journal of the Movement Disorder Society.

[31]  R. Monie,et al.  Occasional Review , 2022 .